Close Menu

Brandi Davis-Dusenbery

Mar 15, 2017

Seven Bridges has promoted Brandi Davis-Dusenbery to CEO. She succeeds Co-founder Deniz Kural, who is assuming the role of executive chairman of the board of directors. Davis-Dusenbery was the former senior vice president of science and product for Seven Bridges. Prior to Seven Bridges, she worked as a fellow at Harvard University's Department of Stem Cell and Regenerative Biology.

More Like This

Nov 15, 2019

Path AI: Michael Montalto

Path AI has appointed Michael Montalto its chief science officer. He joins the company from Bristol-Myers Squibb where he was vice president and head of translational sciences, translational medicine. Before that, he was cofounder of and an executive at Omnyx, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center that commercialized diagnostic pathology imaging and software products. Montalto was the molecular imaging and diagnostics advanced technology leader at GE before that. 

Nov 14, 2019

PredictImmune: James Clark

PredictImmune has appointed James Clark as its chief technology officer.

Clark was previously CEO of EnteroBiotix, a developer of microbiome modulating therapeutics.

Prior to his work at EnteroBiotix, he was vice president of clinical laboratory operations at Inivata, chief technology officer at Enterome, vice president of research and development at MDxHealth, and chief operating officer at Response Genetics.

Nov 14, 2019

Sema4: Joel Sendek

Sema4 has appointed Joel Sendek as chief financial officer.

Sendek brings more than 25 years of financial experience in the pharmaceutical and biotechnology sector, including overseeing successful initial public offerings at his last two companies.

Previously, Sendek was CFO at Spero Therapeutics and Forward Pharma. He spent more than 15 years as an equities research analyst at Stifel Financial and Lazard, worked in corporate development at Progenics Pharmaceuticals, and was an investment banking analyst at Goldman Sachs. He holds a BA in biochemistry from Rice University.

Nov 13, 2019

Danaher: Jessica Mega, Pardis Sabeti

Danaher has appointed Jessica Mega and Pardis Sabeti to its board of directors. Mega has been the chief medical and scientific officer at Verily Life Sciences since October 2015, and was previously a cardiologist and senior investigator at Brigham & Women's. She has also been a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group. Mega holds degrees from Stanford University, Yale University School of Medicine, and Harvard School of Public Health.

Sabeti has been an investigator at Howard Hughes Medical Institute since November 2015, and is also a professor at the Center for Systems Biology and the Department of Organismic and Evolutionary Biology at Harvard University. She also teaches in the Department of Immunology and Infectious Diseases at the Harvard School of Public Health. Sabeti holds degrees from the Massachusetts Institute of Technology, University of Oxford, and Harvard Medical School. 

Nov 13, 2019

Abbott: Robert Ford, Miles White

Abbott announced Miles White will be stepping down as CEO on March 31, 2020 after 21 years in the position, and will be replaced by Robert Ford. Ford has been the president and COO of Abbott since October 2018, and was appointed to the board. Before that, Ford was the executive VP of medical devices at the company, and has been at Abbott since 1996. Miles will remain executive chairman of BD's board. 

Nov 12, 2019

Prescient Medicine Holdings: Tony Grover

Tony Grover has been named the chief commercial officer of Prescient Medicine Holdings where he will build and execute go-to-market strategies. Grover was vice president of business development at Banyan Biomarkers. Prior to that, he held various positions at PhotoThera. His immediate focus at Prescient will be the LifeKit Predict test, an in vitro diagnostic test for identifying patients at risk of opioid addiction. The test received breakthrough device designation in February 2018. Another test, LifeKit Prevent, for the detection of precancerous polyps and early-stage carcinomas, received breakthrough device designation in August 2019. 

Nov 11, 2019

LetsGetChecked: Troy Cox

LetsGetChecked appointed Troy Cox to its board. He has more than 30 years of expereience in healthcare, most recently as president and CEO of Foundation Medicine, now part of Roche. Prior to that, he was senior vice president and an officer at Genentech. He joined the board of Sophia Genetics in July.

Nov 07, 2019

Glympse Bio: Tracey Dawson

Glympse Bio, a firm developing non-invasive disease detection and monitoring technology, has named Tracey Dawson as chief commercial officer and head of strategy. Dawson joins Glympse from Biogen, where she was VP of global product development and commercialization for the multiple sclerosis franchise. Prior to that she was group vice president and head of the US genetic disease franchise for Shire. She has also worked for Genentech and Eli Lilly, and holds a PhD in physical organic chemistry from the University of Hull.

Nov 07, 2019

Epify: Leander Van Neste

Epify, a company developing epigenetic biomarkers for cancer diagnosis, has appointed Leander Van Neste as chief scientific officer. Van Neste joins Epify from miDiagnostics, where he served as vice president of scientific and clinical affairs. He has also served as vice president of clinical and scientific affairs for MDxHealth. Van Neste also simultaneously held academic appointments, including as a professor at Ghent University from 2015 to 2018, and an assistant professor at Universiteit Maastricht from 2013 to 2016. Prior to this he was a visiting research associate at Johns Hopkins School of Medicine.

Nov 06, 2019

LabCorp: Brian Caveney, Mark Schroeder, John Ratliff

Laboratory Corporation of America has named Brian Caveney executive vice president and president of Diagnostics, and Mark Schroeder executive vice president and president of Diagnostics laboratory operations and global supply chain. Also, John Ratliff, CEO of LabCorp's Covance business, is leaving the company to pursue another opportunity. The changes took effect immediately. 

Caveney joined LabCorp as CMO in 2017. Before that he was CMO of Blue Cross Blue Shield of North Carolina. Schroeder has been with LabCorp since 2007 and assumed the role of enterprise-wide chief supply chain officer in 2016. 


Nov 05, 2019

Congenica: Heiner Dreismann

Heiner Dreismann has been appointed as a non-executive director and senior independent director of UK genome analysis firm Congenica. Previously, he was president and CEO of Roche Molecular Systems. He was also head of global business development at Roche Diagnostics and a member of Roche's global diagnostics executive committee. Since leaving Roche, he has been on the board of biotechnology and healthcare companies in the US, Europe, and Israel.

Nov 05, 2019

Accelerate Diagnostics: Roland Diggelmann

Roland Diggelmann has been appointed to Accelerate Diagnostics' board of directors. Diggelmann is currently CEO of Smith+Nephew, a British medical equipment manufacturing company, having recently succeeded Namal Nawana, the former CEO of Alere. Diggelmann previously served as CEO of Roche Diagnostics, and also worked in the orthopedics sector at Sulzer Orthopedics and Zimmer Group. 

Nov 05, 2019

Section 32: Steven Kafka

Former Foundation Medicine President and COO Steven Kafka has joined venture capital fund Section 32 as a managing partner. He is currently executive chairman at Thrive Earlier Detection and at ArcherDX and will continue in these roles. He joins Section 32 from Third Rock Ventures, where he was a partner and venture partner and which he joined after leaving Foundation Medicine. Prior to that, he worked at Aileron Therapeutics, Infinity Pharmaceuticals, Millennium Pharmaceuticals, Strategic Decisions Group, and Forrester Research. Kafka holds a PhD in political economy and government from Harvard University and an AB in economics and political science from Stanford University. At Section 32, he joins managing partner Michael Pellini, the former CEO of Foundation Medicine.

Nov 05, 2019

Biodesix: Scott Hutton, David Brunel

Biodesix announced Scott Hutton will become the firm's CEO, effective Jan. 1, 2020. Current CEO David Brunel will become the chairman and will continue in a day-to-day advisory capacity assisting with strategic direction and key partnerships, the company said. He is a cofounder of Biodesix and has led the firm for more than 13 years.

Hutton is currently Biodesix's COO and has more than 20 years of experience in the medical device, medical technology, and diagnostics industries. Prior to joining Biodesix, he was senior vice president and general manager of vascular interventions at Spectranetics, and VP, GM of neurosurgery at Medtronic. 

Nov 05, 2019

PredictImmune: Steven Martin

Cambridge, UK-based PredictImmune has appointed Steven Martin to its board. Martin is currently the managing partner of Paxton Advisors, an advisory and consulting firm based in Omaha, Nebraska. He was previously the president and CEO of Blue Cross and Blue Shield of Nebraska, and also belonged to the company's board of directors from 2002 to 2018. Martin was the founding board chair of Think Whole Person Healthcare, a primary care clinic and pharmacy in Nebraska.